The Cornerstone Therapy for Adrenocortical Carcinoma and Global Guidelines Update

　　Mitotane,the sole FDA-approved medication for adrenocortical carcinoma(ACC),has been reinstated as the preferred adjuvant treatment by the National Comprehensive Cancer Network(NCCN)in its 2026 guidelines.This pivotal endorsement solidifies Mitotane's role in managing this rare but aggressive cancer.

　　I.Mitotane:The"Precision Sword"Against ACC

　　Mitotane(o,p'-DDD),a synthetic DDT analogue marketed as Lysodren,targets cancer cells through triple-action mechanisms:

　　1.Disrupting Adrenal Cortex:Damages mitochondrial function to halt cortisol production,starving hormone-dependent tumors.

　　2.Apoptosis Induction:Sabotages mitochondrial respiration,triggering endoplasmic reticulum stress and cell death.

　　3.Sustained Bioavailability:Metabolites accumulate for prolonged therapeutic concentrations.

　　As the only FDA and EMA-approved drug,Mitotane is indispensable for both adjuvant care and extending survival in advanced ACC cases.

　　II.NCCN 2026 Update:Consolidating Mitotane's Core Status

　　Key NCCN recommendations(Version 1.2026):

　　●Mandatory for High-Risk Patients:Post-surgery adjuvant therapy is imperative for patients with residual disease,advanced staging,or high Ki-67 expression.

　　●Blood Level Benchmark:Maintaining 14-20 mg/L plasma concentration significantly boosts 5-year relapse-free survival rates to~60%(per Berruti et al.).

　　III.Precision Dosing:Balancing Efficacy and Safety

　　1.Escalation Protocol:

　　○Initial dose:2-6g/day in 3-4 divided doses.

　　○Maintenance therapy exceeding 2 years,adjusted for tolerance.

　　2.Critical Monitoring:

　　○Biweekly plasma Mitotane measurements.

　　○Regular assessments of adrenal function,liver enzymes,and blood counts.

　　IV.Managing Side Effects:A Delicate Balance

　　Mitotane's efficacy requires vigilant side effect management:

　　●Adrenal Insufficiency:Universal occurrence necessitating concurrent corticosteroid replacement(e.g.,hydrocortisone).

　　●Neurotoxicity:Drowsiness,vertigo,ataxia,particularly at high concentrations.

　　●Gastrointestinal Issues:Nausea,vomiting,diarrhea requiring supportive care.

　　●Contraindications:Pregnancy contraindicated;avoid co-administration with warfarin or other CYP3A4-sensitive drugs.

　　V.Global Cost Comparison:Affordable Alternatives

　　●Branded Lysodren:Boxes(500mg x 100 tablets),incurring substantial long-term expenses.

　　●Cost-Effective Generics:

　　○Lucius Pharmaceuticals(Laos):XX units per box(1/3rd of brand price).

　　○AEC Pharma(Laos)–Mytanne:XX units.

　　(Prices subject to market fluctuations;verify with suppliers.)

　　VI.Future Horizons:Combos and Novel Agents

　　Ongoing research holds promise:

　　●Immunotherapy Synergy:Mitotane+PD-1 inhibitors showing preclinical potential.

　　●Targeted Therapies:IGF-1R/VEGF inhibitors paired with Mitotane in trials.

　　●Next-Gen Mitotane:Development of less-toxic analogues.

　　Conclusion:

　　Mitotane’s success hinges on meticulous monitoring,multidisciplinary care(MDT),and personalized regimens.With vigilant medical collaboration,patients can maximize its life-saving potential while mitigating risks.